http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110964810-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2018-09-29^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-04-29^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-04-29^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110964810-B |
| titleOfInvention | Application of HOXA7 and HOXA9 methylation detection reagent in preparation of lung cancer diagnostic reagent |
| abstract | The invention belongs to the field of gene diagnosis, and relates to an application of a detection reagent which takes sputum as a detection sample and takes methylation of HOXA7 and HOXA9 as detection objects in preparation of a lung cancer diagnosis reagent. According to the invention, HOXA7 and HOXA9 are jointly used as tumor markers for detecting lung cancer in sputum for the first time, the sensitivity of the lung cancer tumor markers in the sputum is as high as 97.1%, the specificity of the lung cancer tumor markers is as high as 90.9%, the detection sensitivity of the lung cancer tumor markers is higher than that of the lung cancer tumor markers reported in the prior art, especially the sensitivity of the lung cancer tumor markers in adenocarcinoma is even up to 100%, and the lung cancer tumor markers have great application values in detection and diagnosis of the adenocarcinoma. |
| priorityDate | 2018-09-29^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 181 of 181.